Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.15M Sell
50,175
-22,278
-31% -$1.55M 0.04% 247
2025
Q4
$4.81M Buy
72,453
+8,296
+13% +$536K 0.06% 238
2025
Q3
$4.32M Hold
64,157
0.05% 231
2025
Q2
$5.6M Hold
64,157
0.08% 189
2025
Q1
$4.38M Sell
64,157
-151,653
-70% -$12.4M 0.07% 201
2024
Q4
$16.8M Buy
215,810
+10,320
+5% +$764K 0.23% 91
2024
Q3
$13.8M Buy
+205,490
New +$16.9M 0.21% 106
2024
Q1
Sell
-238,689
Closed -$29.6M 345
2023
Q4
$29.6M Buy
238,689
+3,752
+2% +$383K 0.65% 36
2023
Q3
$21.9M Buy
234,937
+188,451
+405% +$21.2M 0.49% 53
2023
Q2
$5.97M Sell
46,486
-13,045
-22% -$1.58M 0.14% 143
2023
Q1
$6.92M Sell
59,531
-6,048
-9% -$677K 0.18% 118
2022
Q4
$7.43M Buy
+65,579
New +$7.2M 0.21% 102

Other funds holding DXCM

LBP AM's DXCM Position: Q1 2026 in Review

LBP AM reduced its DexCom (DXCM) stake by 31% in Q1 2026, selling an estimated $1.55M and leaving 50,175 shares worth $3.15M. The position accounts for 0.04% of the portfolio, ranked #247.

LBP AM first reported a position in DXCM in Q4 2022 and has held it in 12 quarters since. The position peaked at $29.6M in Q4 2023. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.

  • LBP AM held 50,175 shares of DexCom worth $3.15M as of Q1 2026.
  • LBP AM sold 22,278 DexCom shares in Q1 2026, an estimated $1.55M.
  • DexCom made up 0.04% of LBP AM's portfolio in Q1 2026, its #247 holding.
  • LBP AM first reported a position in DexCom in Q4 2022 and has held it in 12 quarters since.
  • LBP AM's DexCom position peaked at $29.6M in Q4 2023.
  • 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.

Based on LBP AM's 13F filing for Q1 2026, filed 27 Apr 2026.